Optiscan Imaging (ASX:OIL) began its first in-human breast cancer clinical study at the Royal Melbourne Hospital to assess surgical margins in patients receiving treatment for breast cancer using its imaging devices, according to a Monday Australian bourse filing.
The 50-patient study will welcome patients for recruitment for in vivo clinical assessment of breast cancer margins following a lumpectomy procedure. It will use Optiscan's InVue precision surgery and InForm digital pathology imaging devices.
The study completed site initiation.
It will use the data for submissions to the US Food and Drug Administration.
The firm's shares jumped 10% on market close on Monday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。